Myelodysplastic syndrome (deletion 5q) - lenalidomide: equality impact assessment - guidance development
History
Documents created during the development process.
Myelodysplastic syndrome (deletion 5q) - lenalidomide: equality impact assessment - guidance development
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination 2
-
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: final appraisal determination document
-
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report (PDF 2.3 MB)
Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consulation 2
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consulation 2
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation document 2 information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report (PDF 2.53 MB)
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final appraisal determination document
-
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report (PDF 2.62 MB)
Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: appraisal consultation document information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report information
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report (PDF 8.67 MB)
Myelodysplastic syndrome (deletion 5q) - lenalidomide: response to comments on the draft scope and provisional matrix
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: response to comments on the draft scope and provisional matrix
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: equality impact assessment - scoping
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: equality impact assessment - scoping
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final scope
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final scope
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final scope (PDF 50 KB)
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final matrix
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final matrix
-
Myelodysplastic syndrome (deletion 5q) - lenalidomide: final matrix (PDF 56 KB)
Appendix B - draft scope for consultation (pre-referral) - March 2011
-
Appendix B - draft scope for consultation (pre-referral) - March 2011
-
Appendix B - draft scope for consultation (pre-referral) - March 2011 (PDF 58 KB)
Appendix C - provisional matrix (pre-referral) - March 2011
-
Appendix C - provisional matrix (pre-referral) - March 2011
-
Appendix C - provisional matrix (pre-referral) - March 2011 (PDF 60 KB)